10,062 results match your criteria cell arteritis

Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis.

Int J Rheum Dis 2021 Apr 13. Epub 2021 Apr 13.

Departments of Rheumatology, Nuclear Medicine and Anatomical Pathology, Royal North Shore Hospital, Sydney, NSW, Australia.

Aim: Diagnosing and monitoring vascular activity in giant cell arteritis (GCA) is difficult due to the paucity of specific serological biomarkers. We assessed the utility of 8 novel biomarkers in an inception cohort of newly suspected GCA patients.

Method: Consecutive patients were enrolled between May 2016 and December 2017. Read More

View Article and Full-Text PDF

[An update on giant cell arteritis].

Rev Med Chil 2020 Nov;148(11):1619-1629

Departamento de Radiología, Clínica Las Condes, Santiago, Chile.

Giant cell arteritis (GCA) is a primary granulomatous systemic vasculitis involving the aorta and its main branches that affects people aged over 50 years with a genetic predisposition. Its main phenotypes are cranial and extracranial involvement, with or without symptoms of polymyalgia rheumatica. These phenotypes can overlap. Read More

View Article and Full-Text PDF
November 2020

[Lower limb ischemia in giant cell arteritis. Report of one case].

Rev Med Chil 2020 Oct;148(10):1513-1517

Departamento de Cirugía Vascular y Endovascular, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Giant cell arteritis is more common in women older than 60 years, is associated with systemic inflammation symptoms and mainly involves the aortic arch and cranial arteries, specially the temporal artery. Symptomatic lower extremity arterial stenosis or occlusion is uncommon and can lead to limb loss. We report a 73-year-old woman presenting with a one-month history of lower extremity intermittent claudication of sudden onset. Read More

View Article and Full-Text PDF
October 2020

Arm claudication due to giant cell arteritis.

Postgrad Med J 2021 Apr 9. Epub 2021 Apr 9.

Department of General Medicine, Chiba University Hospital Department of General Medicine, Chiba, Japan.

View Article and Full-Text PDF

Myeloproliferative neoplasms and clonal hematopoiesis in patients with giant cell arteritis: a case-control and exploratory study.

Rheumatology (Oxford) 2021 Apr 9. Epub 2021 Apr 9.

Department of Internal Medicine, Cochin Hospital, National Referral Center for Rare Systemic Autoimmune Diseases, Paris University, Paris, France.

Objectives: Giant cell arteritis (GCA) is a large vessel vasculitis for which triggering factors remain unknown. Clonal hematopoiesis (CH) was associated with atherosclerosis through the induction of inflammation in myeloid cells, and data suggest that CH expansion and inflammation may support each other to induce a proinflammatory loop. Our objective was to describe the impact of JAK2p. Read More

View Article and Full-Text PDF

Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.

Rheumatology (Oxford) 2021 Apr 8. Epub 2021 Apr 8.

Rheumatology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Italy.

Objectives: Efficacy evaluation of giant cell arteritis (GCA) treatment is primarily based on non-specific symptoms and laboratory markers. We aimed to assess the change in vascular inflammation in patients with large vessel (LV)-GCA under different treatments using [18F]FDG PET/CT.

Methods: Observational study on patients with new-onset, active LV-GCA starting treatment with either prednisolone monotherapy (PRED) or combination with methotrexate (MTX) or tocilizumab (TOC). Read More

View Article and Full-Text PDF

Clinical and FDG-PET/CT correlates in patients with polymyalgia rheumatica.

Clin Exp Rheumatol 2021 Mar 30. Epub 2021 Mar 30.

Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Italy.

Objectives: We aimed to evaluate joint and vessel uptake in patients with polymyalgia rheumatica (PMR) by FDG-PET and correlate it with clinical findings.

Methods: Consecutive PMR patients, without clinical signs of giant cell arteritis, underwent a standardised clinical examination and FDG-PET/CT. Controls were consecutive subjects undergoing FDG-PET for the suspicion of neoplasm not confirmed by the examination. Read More

View Article and Full-Text PDF

High incidence of giant cell arteritis during the COVID-19 pandemic: no causal relationship but possible involvement of stress.

Clin Exp Rheumatol 2021 Apr 1. Epub 2021 Apr 1.

Bacteriology-Virology-Hygiene Department, Dupuytren University Hospital, Limoges, and UMR INSERM 1092 RESINFIT, University of Limoges, France.

View Article and Full-Text PDF

Cervical duplex ultrasound for the diagnosis of giant cell arteritis with vertebral artery involvement.

J Neuroimaging 2021 Apr 5. Epub 2021 Apr 5.

Second Department of Neurology, National & Kapodistiran University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece.

Giant cell arteritis (GCA) is a systemic inflammatory arteriopathy of medium and large-sized arteries, predominantly affecting branches of the external carotid artery. Ischemic stroke has been reported in 2.8-7% of patients diagnosed with GCA. Read More

View Article and Full-Text PDF

Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis.

Rheumatol Adv Pract 2021 26;5(1):rkab011. Epub 2021 Feb 26.

Department of Rheumatology, Norfolk & Norwich University Hospital, NHS Foundation Trust, Norwich, UK.

View Article and Full-Text PDF
February 2021

CD8+ T Cells in GCA and GPA: Bystanders or Active Contributors?

Front Immunol 2021 18;12:654109. Epub 2021 Mar 18.

Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

Vasculitis refers to inflammation of blood vessels and can cause a variety of serious complications depending on which vessels are affected. Two different forms of vasculitis are Giant Cell Arteritis (GCA) and Granulomatosis with Polyangiitis (GPA). GCA is the most common form of vasculitis in adults affecting the large arteries and can lead to visual impairment and development of aneurysms. Read More

View Article and Full-Text PDF

Sternoclavicular Joint Hypertrophy Involved in Polymyalgia Rheumatica.

Intern Med 2021 Apr 5. Epub 2021 Apr 5.

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.

View Article and Full-Text PDF

Scalp Necrosis in Giant Cell Arteritis.

Mayo Clin Proc 2021 Apr;96(4):987-988

Department of Internal Medicine, CHU Nantes, Nantes, France.

View Article and Full-Text PDF

Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments.

ACR Open Rheumatol 2021 Apr 2. Epub 2021 Apr 2.

University of Kansas Medical Center, Kansas City.

This systematic review compares treatment options for patients with giant cell arteritis (GCA) and evaluates the test accuracy of studies used in diagnosing and monitoring GCA. These studies were used to inform evidence-based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) vasculitis management guidelines. A systematic review and search of articles in English in Ovid Medline, PubMed, Embase, and the Cochrane Library was conducted. Read More

View Article and Full-Text PDF

The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature.

Life (Basel) 2021 Mar 20;11(3). Epub 2021 Mar 20.

Department of Rheumatology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.

Background: The human anti-IL-6 receptor antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA). It is observed that CRP levels drop quickly after starting TCZ treatment. This may lead to misinterpretation of laboratory results when accessing the patient with infectious disease while on TCZ. Read More

View Article and Full-Text PDF

A Diagnostic Algorithm Based on a Simple Clinical Prediction Rule for the Diagnosis of Cranial Giant Cell Arteritis.

J Clin Med 2021 Mar 10;10(6). Epub 2021 Mar 10.

Division of Vascular Medicine, Medical Clinic and Policlinic IV, Hospital of the Ludwig-Maximilians-University, 80336 Munich, Germany.

Background: Risk stratification based on pre-test probability may improve the diagnostic accuracy of temporal artery high-resolution compression sonography (hrTCS) in the diagnostic workup of cranial giant cell arteritis (cGCA).

Methods: A logistic regression model with candidate items was derived from a cohort of patients with suspected cGCA ( = 87). The diagnostic accuracy of the model was tested in the derivation cohort and in an independent validation cohort ( = 114) by receiver operator characteristics (ROC) analysis. Read More

View Article and Full-Text PDF

An immunohistochemical analysis of fibroblasts in giant cell arteritis.

Ann Diagn Pathol 2021 Mar 1;52:151728. Epub 2021 Mar 1.

Department of Internal Medicine, Dupuytren Hospital, Limoges, France; EA3842-CaPTuR, Contrôle de l'Activation Cellulaire, Progression Tumorale et Résistance thérapeutique, Faculty of Medicine, Limoges, France.

Background: Giant cell arteritis (GCA) is a systemic vasculitis of large and medium vessels characterized by an inflammatory arterial infiltrate. GCA begins in the adventitia and leads to vascular remodeling by promoting proliferation of myofibroblasts in the intima. The morphology of the fibroblasts in the adventitia in GCA is unclear. Read More

View Article and Full-Text PDF

Comment on: Evaluation of adjunctive mycophenolate for large vessel giant cell arteritis. Reply.

Maira Karabayas

Rheumatol Adv Pract 2021 26;5(1):rkab012. Epub 2021 Feb 26.

Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen.

View Article and Full-Text PDF
February 2021

Ultrasound for diagnosis and follow-up of chronic axillary vasculitis in patients with long-standing giant cell arteritis.

Ther Adv Musculoskelet Dis 2021 19;13:1759720X21998505. Epub 2021 Mar 19.

Department of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Venusberg-Campus 1, Bonn, Nordrhein-Westfalen 53127, Germany.

Aims: To assess intima-media thickness (IMT) changes measured by ultrasound in axillary arteries of giant cell arteritis (GCA) patients over time and to calculate an ultrasound cut-off value for the diagnosis of chronic axillary artery involvement in patients with longstanding GCA.

Methods: Ultrasound of both axillary arteries was performed in 109 GCA patients at time of diagnosis and at several follow-up visits and in 40 healthy controls (HCs). IMT determined at the prospective follow-up visit was compared between GCA patients with (axGCA) and without (non-axGCA) vasculitis of axillary arteries at baseline, as well as with HCs. Read More

View Article and Full-Text PDF

Optic Neuropathy with Headache and Palpable Temporal Arteries Due to Hypertrophic Pachymeningitis Rather than Giant Cell Arteritis.

Ocul Immunol Inflamm 2021 Apr 1:1-4. Epub 2021 Apr 1.

Department of Ophthalmology and Visual Science, Kochi Medical School, Kochi University, Nankoku City, Kochi, Japan.

: To report a case of optic neuropathy diagnosed by color Doppler ultrasonography and Gadolinium-enhanced cerebral magnetic resonance imaging (MRI).: A 79-year-old woman presented with headache and vision loss in her left eye. Although her bilateral temporal arteries were palpable and rope-like, color Doppler ultrasonography showed normal flow in both arteries with no signs of arteritis. Read More

View Article and Full-Text PDF

Hematological Malignancies in Giant Cell Arteritis: a French population-based study.

Rheumatology (Oxford) 2021 Apr 1. Epub 2021 Apr 1.

Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.

Objectives: An increased risk of hematological malignancies (HM) has been reported in giant cell arteritis (GCA) patients. Our study aimed to investigate the incidence and the type of HM occurring in GCA.

Methods: All patients with GCA and HM living in Côte D'Or (France) were identified by crossing data from the RHEMCO (Registre des Hémopathies Malignes de Côte d'Or) and those having a positive temporal artery biopsy between 1st January 2001 and 31 December 2018. Read More

View Article and Full-Text PDF

A Review of the Dermatological Complications of Giant Cell Arteritis.

Clin Cosmet Investig Dermatol 2021 25;14:303-312. Epub 2021 Mar 25.

Department of Rheumatology, Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Giant cell arteritis (GCA) is characterized by granulomatous inflammation of large and medium-sized vessels. It is the most common vasculitis among elderly people in Europe and North America. GCA usually presents with ischemic cranial manifestations such as headache, scalp tenderness, visual manifestations, and claudication of the tongue and jaw. Read More

View Article and Full-Text PDF

Pulmonary Involvement in Primary Systemic Vasculitides.

Rheumatology (Oxford) 2021 Mar 31. Epub 2021 Mar 31.

Vasculitis Clinic, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.

Objectives: This study describes the spectrum and initial impact of pulmonary manifestations in the primary systemic vasculitides.

Methods: Description and comparison of pulmonary manifestations in adults with Takayasu's arteritis (TAK), giant cell arteritis (GCA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN), and IgA vasculitis (IgAV), using data collected within the Diagnostic and Classification Criteria in Vasculitis (DCVAS) study.

Results: Data from 1952 patients with primary vasculitides were included: 170 TAK, 657 GCA, 555 GPA, 223 MPA, 146 EGPA, 153 IgAV, and 48 PAN. Read More

View Article and Full-Text PDF

Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.

Semin Arthritis Rheum 2021 Mar 18;51(2):469-476. Epub 2021 Mar 18.

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Objective: The randomized, placebo (PBO)-controlled GiACTA trial demonstrated the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA). The present study evaluated the efficacy of TCZ in patients with GCA presenting with polymyalgia rheumatica (PMR) symptoms only, cranial symptoms only or both PMR and cranial symptoms in the GiACTA trial.

Methods: In GiACTA, 250 patients with GCA received either TCZ weekly or every other week plus a 26-week prednisone taper or PBO plus a 26- or 52-week prednisone taper. Read More

View Article and Full-Text PDF

Chest discomfort leading to the diagnosis of pulmonary artery aneurysm due to isolated main pulmonary arteritis involving giant cells: a case report.

Acta Chir Belg 2021 Apr 8:1-5. Epub 2021 Apr 8.

Department of Cardiovascular Surgery, CHU Liege, Liege, Belgium.

Background: Isolated pulmonary artery vasculitis is an uncommon cause of pulmonary artery aneurysm with very few reported cases in the literature.

Patients And Methods: We hereby present the case of a 70-year-old man with occasional episodes of exertional chest discomfort. Our investigations revealed an expanding aneurysm of the main pulmonary artery extending to the proximal portion of the right branch. Read More

View Article and Full-Text PDF

A retrospective analysis on arteritis after administration of granulocyte colony-stimulating factor.

Ann Hematol 2021 May 30;100(5):1341-1343. Epub 2021 Mar 30.

Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo, 113-8655, Japan.

View Article and Full-Text PDF

Functional MRI of the Lungs Using Single Breath-Hold and Self-Navigated Ultrashort Echo Time Sequences.

Radiol Cardiothorac Imaging 2020 Jun 25;2(3):e190162. Epub 2020 Jun 25.

Department of Diagnostic and Interventional Radiology, University Hospital Würzburg, Oberdürrbacher Strasse 6, 97080 Würzburg, Germany (J.F.H., S.V., C.M., L.M.P., T.A.B., H.K., A.M.W.); and Department of Application Development, Siemens Healthcare, Erlangen, Germany (T.B., J.P.).

Purpose: To evaluate three-dimensional (3D) ultrashort echo time (UTE) MRI regarding image quality and suitability for functional image analysis using gradient-echo sequences in breath-hold and with self-navigation.

Materials And Methods: In this prospective exploratory study, 10 patients (mean age, 21 years; age range, 5-58 years; five men) and 10 healthy control participants (mean age, 25 years; age range, 10-39 years; five men) underwent 3D UTE MRI at 3.0 T. Read More

View Article and Full-Text PDF